Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 60 clinical trials
None
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days. Once the patient has received 5 doses of daunorubicin, subsequent therapy will be at …

  • 0 views
  • 06 Nov, 2021
  • 1 location
None
Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

This is a randomized, double-blind, placebo-controlled phase II study evaluating the safety and efficacy of Atezolizumab when combined with immunogenic chemotherapy in subjects with metastatic triple-negative breast cancer. Atezolizumab, pegylated liposomal doxorubicin and cyclophosphamide are the Investigational Medicinal Products (IMPs).

epidermal growth factor
immunostimulant
serum pregnancy test
immunohistochemistry
erbb2
  • 392 views
  • 07 May, 2021
  • 7 locations
None
Anlotinib Hydrochloride for Soft Tissue Sarcoma Patients.

Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR), Platelet-Derived Growth Factor Receptor(PDGFR), and tumor cell proliferation related kinase c-Kit kinase. Anlotinib is an efficient second line therapeutic agent in treatment for …

anthracyclines
angiosarcoma
anlotinib
platelet count
synovial sarcoma
  • 0 views
  • 25 Mar, 2021
  • 1 location
None
The p53 Breast Cancer Trial

This is a multicenter, open labeled, phase 2 clinical trial, where patients are stratified to one of two treatment groups based on upfront TP53 mutation status; i.e. TP53 mutated vs. TP53 wt disease, and treated with dose-dense cyclphosphamide. Furthermore, patients included are stratified based on tumor stage; i.e. locally advanced …

  • 20 views
  • 15 Jun, 2021
  • 5 locations
None
Comparison of Oral Cyclophosphamide vs Doxorubicin in 65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients

Most advanced or metastatic soft tissue sarcoma (STS) are unfortunately incurable, making the preservation of the patient's quality of life a major goal, along with prolonging survival. Age is not a criterion for not providing effective treatment, but the goals of treatment change with age and must be integrated into …

  • 0 views
  • 07 Oct, 2021
  • 1 location
None
FUSCC Refractory TNBC Umbrella (FUTURE)

This is a Phase Ib/II, open-label, umbrella study evaluating the efficacy and safety of multiple targeted treatment in patients with refractory metastatic TNBC.The specific grouping of patients' depends on FUSCC 500+ gene panel testing and IHC subtype staining.

parp inhibitor
EGFR
chemotherapy regimen
solid tumour
capecitabine
  • 22 views
  • 23 Jan, 2021
  • 1 location
None
Rituximab Combination Chemotherapy and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth …

antibody therapy
follicular lymphoma
hodgkin's disease
ibritumomab tiuxetan
rituximab
  • 19 views
  • 07 Nov, 2020
  • 1 location
None
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML

Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control parameter for the optimal therapy tactics. Patients with initially high-risk group and those with high MRD after 2 initial courses of chemotherapy …

  • 1 views
  • 22 Jan, 2021
  • 3 locations
None
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Recent clinical studies showed that breast cancer patients especially for those with lymph node metastasis may benefit from dose-dense chemotherapy, like adriamycin and cyclophosphamide (AC) q2w4 paclitaxel (P) q2w4. However, the studies on dose-dense (dd) regimen chemotherapy is mostly based on postoperative adjuvant chemotherapy and the optimum of dose-dense chemotherapy …

  • 0 views
  • 20 Aug, 2021
  • 1 location
None
Clinico-biological Data Collection Study of Metastatic Breast Cancer

RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective …

immunostimulant
progesterone receptor
erbb2
HER2
metastasis
  • 1 views
  • 29 Jun, 2021
  • 2 locations